ALNARA PHARMACEUTICALS
Alnara Pharmaceuticals, Inc. is dedicated to developing novel protein therapeutics for the treatment of metabolic diseases. The company's innovative approach focuses on designing effective protein therapies that can be orally delivered directly to the gastrointestinal tract without being absorbed into the bloodstream.
ALNARA PHARMACEUTICALS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2008-01-01
Address:
Cambridge, Massachusetts, United States
Country:
United States
Website Url:
http://www.alnara.com
Total Employee:
11+
Status:
Active
Contact:
617-349-3690
Email Addresses:
[email protected]
Total Funding:
55 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Google Universal Analytics Amazon Organization Schema
Similar Organizations
Allena Pharmaceuticals
Allena Pharmaceuticals develops and commercializes non-systemic protein therapeutics to treat metabolic and orphan diseases.
Angstrom Pharmaceuticals
Angstrom Pharmaceuticals develops new class of drugs targeting CD44 for the treatment of metastatic diseases and hematological malignancies.
ARTham Therapeutics
ARTham is here to deliver medicines that matter for patients who suffer with debilitating diseases.
BioStratum
BioStratum develops and commercializes therapeutic agents for the treatment of diabetes and diabetic complications.
Cartilix
Cartilix develops and commercializes biomaterials to repair damaged tissues in articular joints and other applications.
Cullinan Pearl
Cullinan Pearl develops an orally available tyrosine kinase inhibitor to target Epidermal Growth Factor Receptor exon 20 mutations.
Ember Therapeutics
Ember Therapeutics develops the power of brown fat biology and insulin sensitization to develop treatments for metabolic diseases.
Fabre-Kramer Pharmaceuticals
Fabre-Kramer Pharmaceuticals was formed to identify, develop and commercialize psychotropic drugs with significant market potential.
Gene Sciences, Inc.
Gene Sciences Inc. is developing novel DNA targeted therapeutics for the treatment of human genetic diseases.
GlycoMira
GlycoMira develops synthetic glycosaminoglycan-based therapeutics for mucosal diseases.
Immunitor
Immunitor develops orally-delivered immunotherapies for a number of serious diseases affecting the world.
Inspiration Biopharmaceuticals
Inspiration Biopharmaceuticals develops recombinant blood coagulation factor products for the treatment of hemophilia.
Noor Pharmaceuticals
Noor Pharmaceuticals develops and commercializes halal vitamins and innovate and create natural wellness solutions.
OncoGenex
OncoGenex develops and commercializes innovative therapies for the treatment of a variety of cancers.
Osprey Pharmaceuticals USA
Osprey Pharmaceuticals USA develops novel protein therapeutics for the treatment of inflammatory and immune diseases.
Resolvyx Pharmaceuticals
Resolvyx Pharmaceuticals develops therapeutics with small molecule lipid mediators for the treatment of inflammatory diseases.
Statim Pharmaceuticals
Statim Pharmaceuticals develops innovative drug delivery solutions that are easy to administer by anyone in emergency situations.
Syntaxin
Syntaxin engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases.
Tivorsan Pharmaceuticals
Tivorsan Pharmaceuticals is a protein therapeutics company that focuses on treating neuromuscular disorders.
Transport Pharmaceuticals
Transport Pharmaceuticals, Inc. develops drug/device combination products for the treatment of dermal diseases. The company offers SoloVir
Current Employees Featured
Founder
Investors List
MPM Capital
MPM Capital investment in Series B - Alnara Pharmaceuticals
Third Rock Ventures
Third Rock Ventures investment in Series A - Alnara Pharmaceuticals
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series A - Alnara Pharmaceuticals
Longwood Fund
Longwood Fund investment in Series A - Alnara Pharmaceuticals
Bessemer Venture Partners
Bessemer Venture Partners investment in Series A - Alnara Pharmaceuticals
Official Site Inspections
http://www.alnara.com
- Host name: a904c694c05102f30.awsglobalaccelerator.com
- IP address: 13.248.169.48
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
